Podcasts about bayer ag

With Justyna Sokolska, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw - Poland, and Maja Cikes, University of Zagreb School of Medicine, Head at the Unit for Heart Failure and Mechanical Circulatory Support, Department of Cardiovascular Diseases, University Hospital Center, Zagreb - Croatia. In this episode of HFA CardioTalk, Justyna Sokolska interviews Maja Cikes on the challenges in management of long-term left ventricular assist device in patients with advanced heart failure. The discussion emphasizes the importance of selecting appropriate patients at the optimal time, examines the adverse events and highlights major ongoing clinical trials.  Recommended readings:  Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial, Mehra MR, et al. JAMA. 2023 Dec 12;330(22):2171-81  Trends and Outcomes of Left Ventricular Assist Device Therapy: JACC Focus Seminar, Varshney AS, et al. J Am Coll Cardiol 2022 Mar 22;79(11):1092-1107 Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry, Cikes M, et al. Eur J Heart Fail 2019 Sep;21(9):1129-41 A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report, Mehra MR, et al. N Engl J Med 2019 Apr 25;380(17):1618-27 This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

This episode of Don't Miss a Beat, recorded at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, explores the evolving landscape of heart failure with preserved ejection fraction (HFpEF) treatment, focusing on the implementation of combination therapies. Hosts Steve Greene, MD, and Muthiah Vaduganathan, MD, MPH, discuss the transition from a previously limited treatment landscape to a new era with multiple proven therapeutic options. To open the episode, Greene argues in favor of rapid-sequence implementation of HFpEF therapies, drawing parallels to the established 4-pillar guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). He highlights 3 key classes of medications—SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and incretin-based therapies—as the foundation of HFpEF treatment. He emphasizes the importance of early and aggressive therapy initiation to maximize clinical benefits and reduce the risk of delayed or missed treatment opportunities among this population. Vaduganathan acknowledges the strength of the data supporting combination therapy but suggests a more risk-based approach, considering the broad clinical variability among HFpEF patients. He advocates for prioritizing rapid implementation in high-risk patients, such as those recently hospitalized, while allowing a more measured approach for lower-risk individuals. The discussion also touches on the role of phenotyping in tailoring treatment decisions, with GLP-1 receptor agonists being particularly relevant for patients with obesity and ARNi potentially benefiting those with mildly reduced ejection fraction. Looking ahead, the hosts preview upcoming trials, including CONFIDENCE and CONFIRMATION, which will evaluate combination therapy strategies in chronic kidney disease and HFpEF populations. They also discuss the potential of fixed-dose combination therapies to simplify implementation and improve adherence. The episode closes with both experts agreeing on the need for a structured, evidence-based approach to HFpEF treatment while emphasizing the importance of translating trial data into real-world practice. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00-Intro 02:30-Argument for Rapid Sequencing 05:32-Argument Against Rapid Sequencing 10:00-Argument for Risk-Based Sequencing 14:25-Pillars of GDMT in HFpEF

In this on-site episode of Don't Miss a Beat from the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, hosts Muthiah Vaduganathan, MD, MPH, and Steve Greene, MD, break down a pair of trials from the meeting: STRIDE and SOUL. STRIDE Trial The STRIDE trial, funded by Novo Nordisk, was a double-blind, randomized, placebo-controlled study initiated in 2020 to evaluate the effects of semaglutide 1.0 mg (Ozempic) on walking distance in patients with type 2 diabetes (T2D) and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial enrolled 792 patients, who were randomized 1:1 to receive semaglutide or placebo for 52 weeks. Participants assigned to semaglutide received an escalating dose regimen (0.25 mg to 1.0 mg). The primary endpoint, the ratio from baseline in maximum walking distance at 52 weeks, favored semaglutide (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). Secondary outcomes further supported semaglutide's benefit. At week 57, the improvement in walking distance was greater with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011). Pain-free walking distance also improved more with semaglutide than with placebo (ETR, 1.11; P = .0046). SOUL Trial The SOUL trial was a double-blind, placebo-controlled, event-driven study designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). The trial enrolled 9650 patients aged ≥50 years and was conducted across 450 centers in 44 countries. Participants were randomized 1:1 to receive semaglutide or placebo, with a mean follow-up of 47.5 months. Primary outcome events occurred in 12.0% of participants receiving semaglutide (3.1 events per 100 person-years) compared with 13.8% in the placebo group (3.7 events per 100 person-years), resulting in a hazard ratio (HR) of 0.86 (95% CI, 0.77–0.96; P = .006). The primary driver of benefit was a 26% reduction in nonfatal myocardial infarction, with additional reductions in nonfatal stroke (12%) and cardiovascular death (7%). No significant improvements in kidney function were observed. Serious adverse events occurred slightly less frequently in the semaglutide group compared with placebo (47.9% vs 50.3%; P = .02). However, gastrointestinal adverse events, including nausea, diarrhea, constipation, and flatulence, were more common in the semaglutide group (5.0% vs 4.4%). Benefits were consistent across subgroups, including participants receiving sodium-glucose cotransporter-2 inhibitors. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00 - Intro 00:50 - STRIDE Background 02:50 - STRIDE Results 08:19 - SOUL Background 10:40 - SOUL Results

With Robert M.A. van der Boon, Erasmus Medical Center, Rotterdam - The Netherlands, and Anuradha Lala, Mount Sinai Fuster Heart Hospital, New York City - USA. In this episode of HFA Cardio talk, we dive into how factors like sex, socio-economics status and ethnicity shape the way heart failure presents and progresses in different populations. We'll discuss why recognizing these differences is critical for accurate diagnosis and effective treatment and highlight practical steps clinicians can take to close the gaps in prevention and care. Papers: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2534 https://academic.oup.com/eurheartj/article/40/47/3859/5652224?login=true https://www.sciencedirect.com/science/article/pii/S1071916421004322?via%3Dihub https://www.sciencedirect.com/science/article/pii/S0002914922010074?via%3Dihub https://www.sciencedirect.com/science/article/pii/S2468266719301082?via%3Dihub https://journals.lww.com/co-cardiology/fulltext/2021/05000/racial_and_ethnic_disparities_in_heart_failure_.12.aspx https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14986   This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

This week's Open Mic guest is Bill Anderson, CEO of Bayer AG. The global company is heavily invested in developing innovative technology for farmers around the world. The company's pursuit of crop genetics, herbicide resistance, chemical crop protection and data management has benefitted farmer goals toward both sustainability and productivity. Anderson tells Agri-Pulse that legal challenges to glyphosate are limiting the company's investments in innovation and may result in eliminating the sale of a herbicide that many farmers consider essential to sustainable production. 

With Henrique Arfsten, Medical University of Vienna, Vienna - Austria and Alexandre Mebazza, Hospital Lariboisiere, Paris - France.  In this episode of HFA CardioTalk, Henrike Arfsten and  Alexandre Mebazaa discuss the importance of rapid initiation and titration of guideline-directed medical heart failure therapy. A focus will be on data from the STRONG-HF trial, which demonstrated safety and efficacy of rapid up-titration following an acute heart failure event. The trial was even stopped early as the benefits of the intensive treatment strategy were overwhelming. Moreover, specific questions are raised, such as the right time to start therapy and how to deal with possible side effects. Mebazaa A, et al. Lancet 2022 Dec 3;400(10367):1938-52 Biegus J, et al. Heart Fail Rev 2024 Sep;29(5):1065-1077 McDonagh TA, et al. Eur J Heart Fail 2022 Jan;24(1):4-131 McDonagh TA, et al. Eur J Heart Fail 2024 Jan;26(1):5-17 This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

When Bill Anderson became CEO of the German pharmaceutical conglomerate Bayer AG in 2023, he found a company with a long history and a robust corporate bureaucracy. The company handbook was 1,300 pages, and layer after layer of management too easily stifled innovation. Anderson, who worked at Genentech earlier in his career, wanted to instill more of an ownership culture, where decisions and information moved more nimbly. Almost two years in, the changes have been significant: The entire company now runs on 90-day review cycles—allowing for quicker course correction and more of a startup feel for the 161-year-old firm. Anderson is this week's guest on Leadership Next. He spoke to Diane and Kristin about the current state of the health care system, the U.S. regulatory environment, and Bayer's newest advancements in Parkinson's treatment, as well as the company's own complicated history. Leadership Next is powered by Deloitte.

With Novi Yanti Sari, Siloam Hospitals, Jakarta - Indonesia, and Mark Petrie, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow - UK. In this episode of the HFA podcast series, we explore the complex relationship between obesity and heart failure, discussing challenges, management strategies, and the latest therapies, while emphasising the importance of integrated care in improving clinical outcomes. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

In dieser Folge ist Matthias Wiencke als IT Learning Expert zu Gast. Wir sprechen über Generative AI und was die Technologie für Personalentwicklung und Learning & Development in Unternehmen bedeutet. Matthias betont die Notwendigkeit, Mitarbeiter für Generative AI zu sensibilisieren und kontinuierliches Lernen zur Nutzung neuer Technologien in der Organisation zu etablieren - Upskilling ist hier das Stichwort. Im Interview teilt er zudem seine Erfahrungen und das Vorgehen im IT-Digital-Transformationsbereich der Bayer AG und welche AI-Lernformate hier etabliert wurden. Die Veränderung durch Generative AI wird Unternehmen nachhaltig verändern. Hier frühzeitig einzusteigen, die Veränderung von Arbeitstätigkeiten mitzudenken und die Weiterentwicklung von Wissen und Skills der Mitarbeitenden in den Fokus zu nehmen, wird also zukunftsentscheidend sein.

With Jasper Brugts, Erasmus Medical Center Rotterdam, Rotterdam - The Netherlands and Floran Sahiti, University Hospital Würzburg and Comprehensive Heart Failure Center Würzburg, Würzburg - Germany. In this episode of the HFA Podcast Series, we will discuss telemonitoring in general, with a main focus on invasive monitoring in heart failure, the current evidence, and the advantages and disadvantages of the systems. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsors.

Das Traditionsunternehmen aus Leverkusen ist im Sturzflug. Wieso sich Bayer mit dem Kauf von Monsanto übernommen hat.

Künstliche Intelligenz (KI) eröffnet als Katalysator für mehr Produktivität, Innovationskraft und Effizienz nicht nur für Unternehmen, sondern auch für Deutschland als Wirtschaftsstandort enorme Wachstumspotenziale. Eine aktuelle Studie des Instituts der Deutschen Wirtschaft (IW) im Auftrag der unter dem Dach des eco Verbands gegründeten Allianz zur Stärkung digitaler Infrastrukturen untersucht genau diese “Spillover-Effekte” von Rechenzentren und beziffert auf Basis einer Unternehmensbefragung die Übertragungseffekte von Datacentern auf die Beschäftigung oder das Umsatzwachstum im Rahmen der KI-Wende. Mit Blick auf den diesjährigen Digital Gipfel sprechen Sidonie und Sven in der aktuellen Folge von “Das Ohr am Netz” mit ihren Gästen über die Ergebnisse der Studie und die Bedeutung digitaler Infrastrukturen für die digitale Transformation und Innovation in Deutschland. Vorgestellt wird die neue Studie von Carsten Kestermann, Director Public Policy bei AWS, Mitglied der eco Allianz und Mitwirkender an der Studie. Im Gespräch mit Sidonie erläutert er die Kernergebnisse und erklärt, welche Handlungsempfehlungen sich aus der Studie in Richtung Politik ergeben. Volker Ludwig, Senior Vice President und Managing Director DACH bei Digital Realty und Mitglied der eco Allianz, berichtet im Gespräch mit Sven, wie sein Unternehmen versucht, das Innovationspotenzial durch Rechenzentren zu maximinieren. Außerdem erklärt er, vor welchen Herausforderungen Rechenzentrumsbetreiber stehen, wenn es darum geht, die enormen Rechenkapazitäten auch in Zukunft sicherzustellen. Bernd Lohmann, CTO bei der Bayer AG, spricht im Interview mit Sven darüber, wie das Unternehmen KI einsetzt, um Innovationen im Chemie- und Pharmabereich hervorzubringen und die Mission des Bayer Konzerns “Health for All - Hunger for None” voranzutreiben. Dabei erklärt er auch, welche Rolle digitale Infrastrukturen in diesem Kontext spielen. Weitere Informationen: Allianz-Studie “Spillover-Effekte von Rechenzentren” Webseite Digital Gipfel 2024 eco Lounge beim Digital Gipfel eco Umfrage zu politischer Meinungsbildung eco Allianz zu EnEfG eco Eckpunktepapier zum EnEfG-Anpassungsgesetz ----------- Redaktion: Christin Müller, Anja Wittenburg, Melanie Ludewig Schnitt: David Grassinger Moderation: Sidonie Krug, Sven Oswald Produktion: eco – Verband der Internetwirtschaft e.V.

Herzlichen Glückwunsch, BAYER LEVERKUSEN! Zum ersten Mal in der Geschichte feiert die Werkself die deutsche Meisterschaft. BOHNDESLIGA gratuliert ganz herzlich! Zusammen mit unserem Gast Nik Staiger (@nik_staiger) analysieren Nils, Etienne, Tobi und Niko, wie XABI ALONSO Vizekusen zum Titelträger geformt hat. Gemeinsam beleuchtet die Bohndeslig-Crew den Verein in all seinen Facetten: von den starken Transfers über Alonsos Spielsystem bis hin zur Unterstützung durch die Bayer AG. Unsere Spieler der Saison heißen Granit Xhaka und Florian Wirtz. Im zweiten Drittel unserer Sendung legen wir einen Fokus auf den Kampf um die EUROPA LEAGUE. EINTRACHT FRANKFURT, SC FREIBURG oder FC AUGSBURG - wer macht es? Etienne sieht (wie üblich) schwarz, was die Chancen seiner EINTRACHT angeht. Nik kennt sich wiederum mit dem SC FREIBUR aus und orakelt: Leicht wird es für die formschwachen Freiburger nicht. Welches Erbe übergibt Christian Streich seinem Nachfolger Julian Schuster? Zum Schluss widmen wir uns ausführlich dem ABSTIEGSKAMPF. Bo Henriksen hat dem FSV MAINZ 05 neues Leben eingehaucht, während sich der VfL BOCHUM dieser Tage als Chaosverein präsentiert. Und was geht eigentlich in MÖNCHENGLADBACH? Niko war vor Ort und berichtet ausführlich über die Situation bei der BORUSSIA. Rocket Beans wird unterstützt von Radio Bob!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 10, 2025.Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerHussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.Faculty/PlannerGeorgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 10, 2025.Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerHussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.Faculty/PlannerGeorgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 10, 2025.Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerHussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.Faculty/PlannerGeorgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 10, 2025.Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerHussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.Faculty/PlannerGeorgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This episode of The Food Professor Podcast features special guest Glenford Jameson, an expert in regulatory, commercial, and advertising law within the food sector. Jameson's insights cover SFCA compliance, labeling, product positioning, and interactions with the Canadian Food Inspection Agency (CFIA).The episode starts with an exciting announcement that Caddle, a leading Canadian consumer panel and research house, has become the exclusive presenting sponsor of the podcast. Caddle offers brands and retailers access to over 10,000 daily active users, facilitating rapid collection and syndication of consumer reviews. https://askcaddle.com/The discussion then moves to current news, starting with Canadian Minister Champagne's efforts to attract foreign grocers to Canada, raising questions about whether this is political posturing or a genuine attempt to address food affordability. The hosts also covered the ongoing European farmers' protests, where farmers expressed discontent by blocking roads and dumping manure.Next, we discuss Metro's latest quarterly results. Metro reported strong sales growth, with a notable increase in food and pharmacy same-store sales and the successful launch of a new distribution center. Despite these positive outcomes, net earnings showed a slight decrease.The episode also touches on Bayer AG's (Monsanto) $2 billion fine. It provides an update on the surge in the use of weight-loss drugs, specifically referencing North Carolina's state employees' insurance plan's spending on such medications.Finally, the podcast highlights Loblaw's charitable efforts, announcing a $1 million investment in community grants to support various organizations. These grants aim to empower historically underrepresented groups in Canada, including black women-led businesses, programs addressing gender-based violence, youth employment, Indigenous entrepreneurs, and 2SLGBTQIA+ community development.Overall, the episode offers a comprehensive overview of the latest trends, legal insights, and corporate initiatives in the food sector.About GlenfordSpecializing in regulatory, commercial, and advertising law, Glenford Jameson is a trusted legal advisor in the food sector. His expertise spans SFCA compliance, labeling, product positioning, and CFIA interactions. A recognized industry thought leader, he's lectured at notable universities, industry associations, and conferences on Canadian Food Law. Glenford's unique perspective at the crossroads of food, tech, and regulation empowers clients with innovative solutions. He's the founder of G.S. Jameson & Company, and his clients include multinationals, SMEs, NGOs, industry associations, and governments.G. S. Jameson & Company: https://law.gsjameson.comCanadian Association for Food Law and Policy: http://foodlaw.caExcellence in Manufacturing Consortium: https://emccanada.orgGood Food Institute: https://gfi.orgEuropean Food Law Association: https://www.efla-aeda.orgAbout UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa.About MichaelMichael is the Founder & President of M.E. LeBlanc & Company Inc. and a Senior Advisor to Retail Council of Canada and the Bank of Canada as part of his advisory and consulting practice. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, Today's Shopping Choice and Pandora Jewellery.Michael has been on the front lines of retail industry change for his entire career. He has delivered keynotes, hosted fire-side discussions with C-level executives and participated worldwide in thought leadership panels. ReThink Retail has added Michael to their prestigious Top Global Retail Influencers list for 2023 for the third year in a row.Michael is also the president of Maven Media, producing a network of leading trade podcasts, including Remarkable Retail , with best-selling author Steve Dennis, now ranked one of the top retail podcasts in the world.Based in San Francisco, Global eCommerce Leaders podcast explores global cross-border issues and opportunities for eCommerce brands and retailers.Last but not least, Michael is the producer and host of the "Last Request Barbeque" channel on YouTube, where he cooks meals to die for - and collaborates with top brands as a food and product influencer across North America

Gabor Steingart präsentiert das Pioneer Briefing

Gabor Steingart präsentiert das Pioneer Briefing

Der altbewährte Grundsatz “Never catch a falling knife” gilt auch für altbewährte Unternehmen. Das hat selbst Apple in diesem Jahr zu spüren bekommen nach einer Reihe von Negativ-News: Preissenkungen in China, Patentstreits in den USA und Abwertungen von Analysten. Doch inzwischen könnte sich der Einstieg in die Aktie schon wieder lohnen. Anschließend geht Birkenstock in die Analyse. Die deutsche Kult-Sandale hat die ersten Quartalszahlen nach dem eher enttäuschenden Börsengang an der Wall Street vorgelegt. Vor diesem Hintergrund die entscheidenden Details der Bilanz und ein Überblick zur Entwicklung der Aktie. Danach folgt das Dax-Update, diesmal steht die Bayer AG im Mittelpunkt. Der Chemie- und Pharmariese aus Leverkusen hat zu kämpfen. Was heißt das für die damit unter Druck geratene Aktie? In der Community Corner kommen diesmal insbesondere risiko- und experimentierfreudige Zocker auf ihre Kosten. Zum Start der Berichtssaison in den USA wird erklärt, wie sich rund um die Veröffentlichung der Bilanzen die Chance auf Gewinne optimieren lässt. Die komplette Ausgabe ist Teil der Pioneer-Membership. Wer noch nicht an Bord ist, kann unser gesamtes Portfolio zunächst testen, dafür gibt es hier ein spezielles Angebot. https://www.thepioneer.de/willkommen

A multinational pharmaceutical company with a dark past becomes the central figure of a contaminated blood product crisis. Prelude: Ryan White is banned from school after contracting HIV. Originally published August 16, 2020. –––-–---------------------------------------- BECOME A VALUEDLISTENER™ Spotify Apple Podcasts Patreon –––-–---------------------------------------- DONATE: SwindledPodcast.com/Support CONSUME: SwindledPodcast.com/Shop WATCH: SwindledVideo.com –––-–---------------------------------------- MUSIC: Deformr –––-–---------------------------------------- FOLLOW: SwindledPodcast.com Instagram Twitter.com TikTok Facebook Thanks for listening. :-) Learn more about your ad choices. Visit podcastchoices.com/adchoices

This Day in Legal History: Hong Kong is Transferred Back to ChinaToday marks a significant date in legal history with the anniversary of the Sino-British Joint Declaration, signed on December 19, 1984. This historic agreement between the United Kingdom and China heralded a major geopolitical shift, as it outlined the terms for transferring sovereignty of Hong Kong to China in 1997. This treaty was not just a transfer of power; it was a unique blend of diplomacy and legal ingenuity.The Declaration was a testament to complex international negotiations, balancing the interests and concerns of both the UK and China. It crafted a "one country, two systems" framework, ensuring that Hong Kong would maintain its capitalist economy and democratic freedoms for at least 50 years post-transition. This framework was unprecedented in international law, symbolizing a delicate balance between sovereignty and local autonomy.The treaty's significance extends beyond its immediate impact on Hong Kong. It set a new standard for international treaties dealing with sovereignty and administrative control, reflecting the evolving nature of global diplomatic relations. Legal scholars and political analysts have since studied the Declaration for its innovative approach to resolving international disputes.In retrospect, the handover of Hong Kong under this treaty has had far-reaching consequences, affecting not just the region but also international relations and discussions about sovereignty and autonomy. As we reflect on this day, the long-term implications and effectiveness of the "one country, two systems" principle continue to be a subject of global interest and debate. The Sino-British Joint Declaration remains a pivotal point in legal and political history, illustrating the complexities of international law and diplomacy.Apple Inc. is urgently modifying its smartwatch software to avoid a looming U.S. ban on its products, potentially impacting its $17 billion business. This initiative involves altering algorithms related to blood oxygen level measurement, a feature claimed by Masimo Corp. to infringe on its patents. The engineering challenge is unprecedented for Apple, especially given the timing around Christmas and the significant market at stake in the U.S.The ban, scheduled for December 25th unless overturned by the White House, has resulted from a decision by the International Trade Commission (ITC). Apple's response includes software updates and exploring other technical and legal avenues. The company has begun adjusting retail strategies, notably altering promotional materials to exclude the Series 9 and Ultra 2 models, which are directly affected by the ban.Apple's stock experienced minimal fluctuation following the news, while Masimo's shares saw an increase. Apple is hopeful that software revisions will suffice to address the issue, although Masimo insists on a hardware change. The dispute centers primarily on hardware patents, challenging Apple's approach of software-based resolution.The import restriction imposed by the ITC complicates Apple's situation, as its smartwatches are assembled overseas. Resolving the dispute solely with software modifications might be difficult, considering the breadth of Masimo's patents. Any hardware changes, however, would necessitate a lengthy process for production, shipping, and regulatory approval, potentially taking months.The blood oxygen feature, central to the dispute, was introduced in the Apple Watch Series 6 in 2020 and is key for monitoring health, particularly during the COVID-19 pandemic. This functionality is also present in later models, whose sales could be halted by the ban. Notably, third-party retailers may continue selling the affected models.Apple's smartwatches have become a significant revenue stream, with sales rising from $9.1 billion to $16.9 billion over five years. These products not only contribute financially but also play a crucial role in keeping users within the Apple ecosystem. The White House's decision on a possible veto remains uncertain, with considerations complicated by the fact that both Apple and Masimo are U.S.-based companies. The situation reflects the complexity of patent disputes and the impact of regulatory decisions on major tech companies.Apple Races to Tweak Software Ahead of Looming US Watch Ban (1)Bayer AG was ordered to pay $857 million in damages to former students and parent volunteers at Sky Valley Education Center in Washington state. This verdict comes after the exposure to polychlorinated biphenyls (PCBs) in the school's lighting system was deemed unsafe, leading to brain damage and other health issues. This case is the eighth such decision in the state, bringing total damages awarded in similar cases to over $1.5 billion. Bayer, which acquired Monsanto in 2018, plans to appeal the verdict and challenges the claims of unsafe PCB levels, while also grappling with legal issues related to its Roundup weed killer and other Monsanto-inherited liabilities.Bayer Hit With $857 Million Verdict on Toxic Monsanto ChemicalsThe latest enrollment data for U.S. law schools shows stability after two volatile years, with a slight decline in first-year Juris Doctor students compared to 2022. This fall, there were 37,886 new law students, a modest decrease from 38,060 the previous year. Despite the overall decline, racial diversity among new law students reached a historic high, with 40% of the new class being students of color. This marks the third consecutive year of record-setting diversity in law school enrollments.The increase in diversity comes just before the U.S. Supreme Court's ban on affirmative action in college admissions, which will impact future admissions cycles. The ban represents a significant change, as this year's class is the last admitted under the affirmative action policies.The Law School Admission Council notes the importance of continuing efforts to promote access, equity, and fairness in the legal profession, especially in light of the Supreme Court's ruling. Despite the ruling, early data shows a 4% increase in new law school applicants, with non-white applicants constituting a slightly higher percentage of the applicant pool compared to last year. This indicates that the ruling has not deterred diverse candidates from pursuing legal education.Final law class admitted before affirmative action ban is most diverse on record | ReutersFirst, you need to know what Pillar 2 is. Pillar 2, part of the Two-Pillar Solution to address tax challenges from digitalization, was introduced on December 20, 2021, by 137 OECD/G20 member jurisdictions. It aims to ensure that large multinational enterprises (MNEs) pay a minimum tax level in each jurisdiction of operation. The rules, spanning about 60 pages, serve as a template for jurisdictions to incorporate into domestic law. They encompass a 15% minimum tax rate, applying to MNEs with over EUR 750 million in consolidated revenues. Exemptions include entities like government and non-profit organizations. The rules calculate the effective tax rate per jurisdiction and require payment of any top-up tax to meet the minimum rate of 15%. In other words, in over simplified terms, a tax haven that taxes an MNE at less than 15%, let's say 10%, potentially leaves on the table an additional 5% in taxes which can be collected by other jurisdictions that the MNE does business in. Pillar 2's global minimum tax thus blunts the efficacy of a tax haven.My column discusses the implications of Pillar Two on MNEs, focusing on the treatment of tax credits. It highlights a potential loophole in the distinction between refundable and non-refundable tax credits under Pillar Two rules. By way of definition, refundable tax credits can exceed the amount of taxes a taxpayer owes, resulting in a refund. Non-refundable tax credits, on the other hand, can only reduce the tax bill to zero and do not result in a refund if they exceed the amount owed.In my column I suggest that refundable tax credits, treated as income rather than tax reductions, might enable state-backed tax avoidance. I argue for a broader approach to evaluating what I'm calling “state fiscal concessions” to multinationals, emphasizing the need for a comprehensive policy that considers all forms of state support, not just tax credits, in the context of global minimum tax compliance. Multinationals Need Universal Treatment on Pillar Two Credits Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YNP865. CME credit will be available until November 26, 2024.Getting to Know the New Desmoid Tumor ICD-10-CM Codes and Why They Matter: Practical Guidance for Integrating the New Codes and Navigating the Implications In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMrinal Gounder, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aadi bioscience; Ayala Pharmaceuticals; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron Pharmaceuticals Inc.; SpringWorks Therapeutics; and TYME Inc.Grant/Research Support from Ayala Pharmaceuticals; Bayer AG; Iterion Therapeutics; and SpringWorks Therapeutics.Faculty/PlannerLinda Holtzman, MHA, RHIA, CCS, CCS-P, CPC, COC, has a financial interest/relationship or affiliation in the form of:Other Financial or Material Support as an Independent Contractor for Desmoid Tumor Research Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YNP865. CME credit will be available until November 26, 2024.Getting to Know the New Desmoid Tumor ICD-10-CM Codes and Why They Matter: Practical Guidance for Integrating the New Codes and Navigating the Implications In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMrinal Gounder, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aadi bioscience; Ayala Pharmaceuticals; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron Pharmaceuticals Inc.; SpringWorks Therapeutics; and TYME Inc.Grant/Research Support from Ayala Pharmaceuticals; Bayer AG; Iterion Therapeutics; and SpringWorks Therapeutics.Faculty/PlannerLinda Holtzman, MHA, RHIA, CCS, CCS-P, CPC, COC, has a financial interest/relationship or affiliation in the form of:Other Financial or Material Support as an Independent Contractor for Desmoid Tumor Research Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YNP865. CME credit will be available until November 26, 2024.Getting to Know the New Desmoid Tumor ICD-10-CM Codes and Why They Matter: Practical Guidance for Integrating the New Codes and Navigating the Implications In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMrinal Gounder, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aadi bioscience; Ayala Pharmaceuticals; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron Pharmaceuticals Inc.; SpringWorks Therapeutics; and TYME Inc.Grant/Research Support from Ayala Pharmaceuticals; Bayer AG; Iterion Therapeutics; and SpringWorks Therapeutics.Faculty/PlannerLinda Holtzman, MHA, RHIA, CCS, CCS-P, CPC, COC, has a financial interest/relationship or affiliation in the form of:Other Financial or Material Support as an Independent Contractor for Desmoid Tumor Research Foundation.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Economic Club Chairman David Rubenstein interviewed the CEO of Bayer AG, Bill Anderson, covering Bayer's innovations in healthcare and agriculture, his plans for revitalizing the company, and the state of the global economy, among other things.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

How do you create a more inclusive workspace? For over 25 years, Dr. Steve Yacovelli has been training organizations like Fortune 500 Greats, The Walt Disney Company, and Bayer AG, and amazing not-for-profits like The Bill & Melinda Gates Foundation. Dr. Steve Yacovelli is the author of the award-winning book Pride Leadership: Strategies for the LGBTQ+ Leader to be the King or Queen of their Jungle.Dr. Steve Yacovelli (“The Gay Leadership Dude™”) is the Owner & Principal of  TopDog Learning Group, LLC – a learning and development, leadership, change management, and diversity and inclusion consulting firm based in Orlando, FL, USA, with affiliates across the globe. He has a mission to create more inclusive workplaces, and in this episode, we talk about: The 6 Competencies of Inclusive and effective leadershipHow to maintain authenticity in a virtual environmentWhat you can do immediately to create a more inclusive workplace - with real examples!What leaders and learning and development professionals can do to create a more Follow Dr. Steve Yacovelli on LinkedIn or InstagramWatch this episode on Youtube Support the show Jill Griffin is on a mission to improve life in the workplace by helping leaders design their next chapter, increase their well-being, intentionality and impact. Jill's executive coaching, strategy, and innovation have generated multi-millions in revenue for the world's largest agencies, start-ups, and well-known brands. She works with individuals, teams, and organizations to create cultures allowing leaders to increase performance and impact while maintaining well-being. Visit JillGriffinCoaching.com for more details on: Book a 1:1 Career Strategy and Executive Coaching HERE CEO Advising and Consulting Gallup CliftonStrengths Corporate Workshops to build a strengths-based culture Team Dynamics training to increase retention, communication, goal setting, and effective decision-making Grab a personal Resume Refresh with Jill Griffin HERE Follow @jillGriffinOffical on Instagram for daily inspiration Connect with and follow Jill on LinkedIn

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Edge-to-edge mitral valve repair The future treatment of chronic heart failure Mythbusters: Is chocolate healthy for the heart? Host: Susanna Price Guests: Carlos Aguiar, Milton Packer and Stephan Windecker Want to watch that episode? Go to: https://esc365.escardio.org/event/1122   Disclaimer This programme is supported by Siemens Healthineers in the form of an educational grant. The scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel, Milton Packer and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme. Stephan Windecker has declared to have potential conflicts of interest to report: payments from Amgen and Medtronic, research funding from Abbott, Amgen, AstraZeneca, Bayer AG, Biotronik, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Guerbet AG, Johnson & Johnson, Medtronic, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi Adventis, V-Wave, Abiomed, Boehringer-Ingelheim, Bristol Myers Squibb, B.Braun, Cordis Medical, Miracor medical, Pharming Tech, CSL Behring, Farapulse Inc., Fumedica, Idorsia, Inari Medical, MedAlliance.

In this month's Digital Health Roundup, Medtech Insight's Marion Webb and Hannah Daniel discuss highlights from their DTA Summit coverage in Washington. Reed Miller talked to Frank Chan, the president of Medtronic's Patient Monitoring, about plans for the patient monitoring as an independent company and Bayer AG's new business unit focusing on digital health. Listen to the podcast via the player below: Medtech Insight articles addressing topics discussed in this episode: Digital Therapeutics Alliance Summit DTA Panel Discusses Future Of Digital Therapeutics, Obstacles To Wider Adoption The Afterlife Of Pear Therapeutics: Korean DTx Maker Discusses Vision For Salvaged Migraine Assets The Frontier Of Digital Therapeutics Regulations Pear Bankruptcy Filing Highlights Difficult Challenges Facing Digital Therapeutics Exec Chat: Medtronic's Chan Discusses Future Of Connected Care In A Stressed System Minute Insight: Bayer Launches Precision Health Unit To Focus On Digital Consumer Health

In May 2019, the husband and wife Alva and Alberta Pilliod won a federal court case against Monsanto. Both of them had developed non-Hodgkin's lymphoma. This cancer causes white blood cells called lymphocytes to grow abnormally throughout the body. The farmers worked decades with the herbicide, which Monsanto claimed is safe to use. In 2015, the International Agency for Research on Cancer (IARC) categorized the active ingredient in Roundup, glyphosate, as a “probable carcinogen.” And this was the basis for the judge's decision to decide in favour of the couple. Bayer AG had to pay a fine of $2 billion because it had acquired Monsanto, the manufacturer of Roundup. One year after the merger, BAYER's share price was still cut in half.  The pharmaceutical giant had signed up for an ever-increasing burden of legal battles. In 2019, 18.000 lawsuits were pending in the US. Most of them due to cancer cases potentially linked to Roundup.  For numerous decades, Monsanto marketed their herbicide as safe to use for farmers and individuals. Most regulatory bodies categorize glyphosate as safe, including - Health Canada Why does the International Agency for Research on Cancer come to a different conclusion than all the other agencies? Possibly because they only consider “publicly available and pertinent studies, by independent experts, free from vested interests.” But apparently, the amount of independent studies on glyphosate-based pesticides is rather limited. How can the world's most-used pesticide have so few independent studies? Is this really a coincidence? The full script with all sources for this episode: https://docs.google.com/document/d/1VO05Vrh37BUA9UoLnAOSJz1pdCF3tzkl/edit?usp=sharing&ouid=115780270029914491641&rtpof=true&sd=true !! Find other sources, key takeaways and links on our blog: ⁠⁠https://redtogreen.ghost.io/what-monsanto-teaches-us-about-biotech/⁠⁠ Support Red to Green ⁠ https://www.patreon.com/RedtoGreen⁠ Get funding for your food science research: ⁠https://en.raps-stiftung.de/foerderbereiche/lebensmittelforschung⁠ More info and links to resources on⁠ https://redtogreen.solutions/  ⁠ Seeds of Science https://www.amazon.com/Seeds-Science-Why-Wrong-GMOs/dp/1472946987 Connect with the host, Marina ⁠https://www.linkedin.com/in/schmidt-marina/⁠ Connect with the host, Frank ⁠https://www.linkedin.com/in/frankkuehne/⁠ Please rate the podcast on Spotify and iTunes!

Is Bayer AG really EVIL? Or have they, like a lot of companies done both really good things - like marketing aspirin and other valuable medicine around the world - and really bad things, like market heroin after they knew it was dangerous, and perform deadly drug experiments on concentration camp victims? Yeah - that last one is real, REAL bad. But - how many corporate hands are truly clean? How many companies buy minerals from conflict zones, or materials from sweatshops? How many other companies today have Nazi ties, or more recent track records of selling products they knew were much deadlier than they were publicly letting on? Today we look at Bayer and Monsanto, and the dirty deeds they've done, but also, we zoom out and look at multinational corporations in general. Should we be more afraid of The State? Or the private sector? Get tour tickets at dancummins.tv Get Scared to Death LIVE tickets at badmagicmerch.com  October  27th, 6P PST/9PM EST. True Tales of Hallow's Eve Horror TWO! Watch the Suck on YouTube: https://youtu.be/rjF7-5y_g3cMerch: https://www.badmagicmerch.comDiscord! https://discord.gg/tqzH89vWant to join the Cult of the Curious private Facebook Group? Go directly to Facebook and search for "Cult of the Curious" in order to locate whatever happens to be our most current page :)For all merch related questions/problems: store@badmagicproductions.com (copy and paste)Please rate and subscribe on iTunes and elsewhere and follow the suck on social media!! @timesuckpodcast on IG and http://www.facebook.com/timesuckpodcastWanna become a Space Lizard?  Click here: https://www.patreon.com/timesuckpodcastSign up through Patreon and for $5 a month you get to listen to the Secret Suck, which will drop Thursdays at Noon, PST. You'll also get 20% off of all regular Timesuck merch PLUS access to exclusive Space Lizard merch. You get to vote on two Monday topics each month via the app. And you get the download link for my new comedy album, Feel the Heat. Check the Patreon posts to find out how to download the new album and take advantage of other benefits.